| Code | CSB-RA011050MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Emapalumab-LZSG, targeting interferon-gamma (IFNG), a critical cytokine central to immune regulation and inflammatory responses. IFNG plays a pivotal role in activating macrophages, enhancing antigen presentation, and coordinating both innate and adaptive immunity. Dysregulated IFNG signaling is implicated in various pathological conditions, including hemophagocytic lymphohistiocytosis (HLH), autoinflammatory disorders, and certain autoimmune diseases where excessive interferon-gamma activity drives tissue damage and systemic inflammation.
Emapalumab-LZSG is an FDA-approved therapeutic antibody that neutralizes interferon-gamma by binding to its soluble form, preventing receptor engagement and downstream signaling. This biosimilar provides researchers with a valuable tool for investigating IFNG-mediated pathways, studying cytokine neutralization mechanisms, and exploring therapeutic interventions in hyperinflammatory conditions. The antibody serves as an essential reagent for preclinical studies examining interferon-gamma biology, immune modulation, and potential treatment strategies for conditions characterized by pathological IFNG activity.
There are currently no reviews for this product.